GlassScriptPhysician profile
Shaukat A Khan
NPI 1477549871
$4,753.03
in general payments reported to CMS, 2019-2025
35 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $747 · 2021: $980 · 2022: $785 · 2023: $640 · 2024: $330 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $766.78 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $503.96 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $383.21 | 2020-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $354.13 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $286.56 | 2019-2025 | Farxiga |
| Esperion Therapeutics, INC. | $246.70 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $243.51 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $240.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.31 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $176.27 | 2019-2021 | |
| Amarin Pharma, INC. | $158.48 | 2019-2021 | |
| Lilly USA, LLC | $131.77 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $110.25 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $109.90 | 2019-2024 | Xarelto, Spravato |
| Eisai INC. | $99.68 | 2020-2021 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaukat Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.